TACR1 and neoplasm: If this would result correctly, it would mean that NK-1 receptor antagonists could inhibit a large number of tumor cell types in which both SP and NK-1 receptors are expressed, and that they could be candidates for broad spectrum antineoplastic drugs [18, 22, 23, 25, 41, 53–55, 178–181].